361 Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

361 Capital’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,809	Closed	-$1.51M	–	429
2018 Q3	$1.51M	Buy	+21,809	New	+$1.65M	0.33%	181
2018 Q1	–	Sell	-39,599	Closed	-$2.12M	–	353
2017 Q4	$2.12M	Buy	+39,599	New	+$2.2M	0.52%	90

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

361 Capital's EGRX Position: Q4 2018 in Review

361 Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 21,809 shares — an estimated $1.51M sold.

361 Capital first reported a position in EGRX in Q4 2017 and held it in 2 quarters. The position peaked at $2.12M in Q4 2017. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

361 Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
361 Capital sold 21,809 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1.51M.
361 Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
361 Capital's Eagle Pharmaceuticals, Inc. position peaked at $2.12M in Q4 2017.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on 361 Capital's 13F filing for Q4 2018, filed 8 Feb 2019.